Hordenine

Hordenine is a phenethylamine alkaloid found naturally in barley, bitter orange, and certain cacti, acting primarily as a substrate for monoamine oxidase (MAO) and a weak adrenergic receptor agonist. Its proposed stimulant and fat-burning effects stem from structural similarity to synephrine and tyramine, though no human clinical trials currently validate these mechanisms.

Origin & History

Hordenine is a naturally occurring alkaloid first isolated in 1906 from germinated barley (Hordeum vulgare) seeds, from which it derives its name. It occurs widely in cereal seedlings (barley ~0.2%, sorghum ~0.1%, proso millet ~0.2%) and cacti species (notably Trichocereus candicans at 0.5-5.0%). As a phenethylamine alkaloid (C₁₀H₁₅NO), it is produced in plants through stepwise N-methylation of tyramine.

Historical & Cultural Context

First isolated by Arthur Heffter in 1894 from the cactus Anhalonium fissuratus (naming it 'anhalin'), hordenine was later found in barley by E. Léger in 1906. Despite occurring naturally in cereals consumed for millennia, no evidence of deliberate traditional medicinal use is documented. The compound has various historical synonyms including anhalin and cactine, reflecting its diverse plant sources.

Health Benefits

• Potential stimulant properties - No human clinical evidence exists; theoretical based on structural similarity to phenethylamines
• Possible antibacterial effects - Documented only in plant systems (PMID: 30609368, 30128579), not in humans
• Marketed for athletic performance - No clinical trials support this use; evidence quality: absent
• Promoted for weight loss - No human studies validate this claim; evidence quality: absent
• Theoretical mood/energy enhancement - No clinical data available; based solely on chemical structure similarity

How It Works

Hordenine (N,N-dimethyltyramine) acts as a substrate and inhibitor of monoamine oxidase type B (MAO-B), potentially slowing the degradation of catecholamines such as dopamine, norepinephrine, and epinephrine, thereby prolonging their activity at adrenergic receptors. It demonstrates weak agonism at beta-2 adrenergic receptors, which theoretically could increase cyclic AMP (cAMP) and promote lipolysis or mild bronchodilation. In vitro and animal studies also suggest inhibition of norepinephrine reuptake transporters (NET), though the concentrations required have not been demonstrated achievable through oral supplementation in humans.

Scientific Research

The research reveals a complete absence of human clinical trials, RCTs, or meta-analyses examining hordenine's efficacy or safety. Available literature consists primarily of phytochemical reviews (PMID: 24257763 on biosynthesis) and plant-based antibacterial studies (PMID: 30609368, 30128579). No human pharmacokinetic, safety, or efficacy data exists in the scientific literature.

Clinical Summary

No peer-reviewed randomized controlled trials in humans have evaluated hordenine as an isolated supplement for any health outcome, including athletic performance, weight loss, or cognitive enhancement. Antibacterial activity has been documented in plant cell systems and in vitro bacterial assays (PMID: 30609368, PMID: 30128579), but these findings have not been translated into human clinical research. Pharmacokinetic data from humans is essentially absent, meaning effective oral dosage ranges, bioavailability, and plasma half-life remain undefined. The totality of evidence for hordenine's efficacy in humans is currently insufficient to support any therapeutic claim.

Nutritional Profile

Hordenine (N,N-dimethyltyramine) is a phenethylamine alkaloid, not a conventional nutrient — it contains no meaningful macronutrients, vitamins, minerals, or fiber. It is a trace alkaloid found naturally in barley malt (Hordeum vulgare) at concentrations of approximately 0.2–0.4 mg/g dry weight, and in smaller amounts in sprouted grains and certain cacti. As a compound, it functions primarily as a monoamine oxidase (MAO) inhibitor and indirect adrenergic agonist. Bioavailability data in humans is essentially absent; animal studies suggest oral absorption occurs, but first-pass metabolism and MAO-mediated degradation likely limit systemic exposure. It is not a source of caloric energy, essential amino acids, or micronutrients in any practical dietary quantity. Its bioactive relevance stems entirely from its alkaloid pharmacology rather than nutritional contribution.

Preparation & Dosage

No clinically established dosage ranges exist for hordenine in humans. Natural dietary intake occurs through barley consumption (containing ~2000 μg/g in seedlings, ~3363-4066 μg/g in malt roots). Dietary supplements include hordenine for athletic performance and weight loss, but no standardized extract concentration or recommended dose is documented in scientific literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hordenine is most frequently combined with phenylethylamine (PEA) because hordenine's MAO-B inhibitory action slows PEA degradation, meaningfully extending PEA's otherwise very short half-life (seconds to minutes) and amplifying its adrenergic and dopaminergic signaling — this is the most pharmacologically documented pairing. Caffeine is commonly co-formulated on the basis of additive adrenergic stimulation via separate mechanisms (adenosine antagonism vs. indirect catecholamine release), though no clinical trial confirms additive or synergistic outcomes specifically with hordenine. Synephrine (from bitter orange) represents a third proposed pairing, as both compounds act on adrenergic receptors (β-2 and β-3 pathways relevant to lipolysis theoretically), though combined cardiovascular risk in the absence of human safety data warrants caution.

Safety & Interactions

Hordenine is a MAO inhibitor substrate, meaning concurrent use with MAO inhibitor medications (e.g., phenelzine, selegiline) or other serotonergic/adrenergic compounds could precipitate hypertensive crisis or serotonin syndrome. As a structural analog of tyramine, individuals sensitive to dietary tyramine — including those with migraines or on MAOIs — face elevated risk from hordenine-containing products. No formal safety studies, teratogenicity data, or pregnancy/lactation guidelines exist, making its use contraindicated in pregnant or breastfeeding individuals by default. Products combining hordenine with caffeine, synephrine, or other stimulants (common in pre-workout formulas) amplify cardiovascular risks including tachycardia and elevated blood pressure.